yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital. . .
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid. .